DB:DPD2

Stock Analysis Report

Executive Summary

Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Imagin Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DPD2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

26.9%

DPD2

0.9%

DE Medical Equipment

-0.6%

DE Market


1 Year Return

-50.0%

DPD2

6.5%

DE Medical Equipment

-20.9%

DE Market

Return vs Industry: DPD2 underperformed the German Medical Equipment industry which returned 6.5% over the past year.

Return vs Market: DPD2 underperformed the German Market which returned -20.9% over the past year.


Shareholder returns

DPD2IndustryMarket
7 Day26.9%0.9%-0.6%
30 Day-25.2%-4.9%-16.6%
90 Day-57.6%-12.0%-26.0%
1 Year-50.0%-50.0%8.1%6.5%-18.6%-20.9%
3 Year-53.7%-53.7%101.2%95.8%-19.0%-25.8%
5 Yearn/a216.5%201.9%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is Imagin Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Imagin Medical undervalued compared to its fair value and its price relative to the market?

6.39x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DPD2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DPD2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DPD2 is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: DPD2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DPD2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DPD2 is overvalued based on its PB Ratio (6.4x) compared to the DE Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Imagin Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Imagin Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Imagin Medical performed over the past 5 years?

-37.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DPD2 is currently unprofitable.

Growing Profit Margin: DPD2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DPD2 is unprofitable, and losses have increased over the past 5 years at a rate of -37.4% per year.

Accelerating Growth: Unable to compare DPD2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DPD2 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.9%).


Return on Equity

High ROE: DPD2 has a negative Return on Equity (-538.45%), as it is currently unprofitable.


Next Steps

Financial Health

How is Imagin Medical's financial position?


Financial Position Analysis

Short Term Liabilities: DPD2's short term assets (CA$1.1M) exceed its short term liabilities (CA$373.4K).

Long Term Liabilities: DPD2 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DPD2 is debt free.

Reducing Debt: DPD2 had no debt 5 years ago.


Balance Sheet

Inventory Level: DPD2 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DPD2's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DPD2 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DPD2 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -42.5% each year


Next Steps

Dividend

What is Imagin Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DPD2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DPD2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DPD2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DPD2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DPD2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

Jim Hutchens

4.17s

Tenure

CA$649,099

Compensation

Mr. Edward James Hutchens, also known as Jim, is the Co-founder and Managing Director of Origin Partners. Mr. Hutchens has been Chief Executive Officer and President of Imagin Medical Inc. since February 2 ...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD459.29K) is about average for companies of similar size in the German market ($USD428.66K).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Edward Hutchens
CEO, President & Director4.17yrsCA$649.10k4.51% CA$210.0k
John Vacha
CFO, Corporate Secretary & Director2.25yrsCA$338.86k0.17% CA$8.1k
Christopher Bleck
Independent Director1.5yrsCA$6.00k0.16% CA$7.3k
Ralph de Vere White
Chairman of Scientific Medical Advisory Board4yrsno datano data
Edward Messing
Member of Scientific Medical Advisory Board3.58yrsno datano data
Ashish Kamat
Member of Scientific Advisory Board1yrno datano data
Robin Atlas
Independent Chairperson of the Boardno dataCA$6.00k0.60% CA$27.7k
Kenneth Daignault
Independent Director3.58yrsCA$71.85k0.16% CA$7.3k
Liam Hurley
Member of Scientific Medical Advisory Board3.5yrsno datano data
Roger Buckley
Member of Scientific Medical Advisory Board3.42yrsno datano data

3.5yrs

Average Tenure

Experienced Board: DPD2's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DPD2 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13%.


Top Shareholders

Company Information

Imagin Medical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Imagin Medical Inc.
  • Ticker: DPD2
  • Exchange: DB
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$7.094m
  • Listing Market Cap: CA$4.652m
  • Shares outstanding: 177.34m
  • Website: https://imaginmedical.com

Location

  • Imagin Medical Inc.
  • 890 West Pender Street
  • Suite 600
  • Vancouver
  • British Columbia
  • V6C 1L9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DPD2DB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2016
IMEX.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 2016
IMECNSX (Canadian National Stock Exchange)YesCommon SharesCACADFeb 2016

Biography

Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/06 00:03
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.